She still calls it Compound 10. Not CPD10, the formal name buried in the patent paperwork, but Compound 10, the way you might refer to a stubborn houseguest you have come to know rather well. Ursula Quitterer has spent close to twenty years getting acquainted with the problem this molecule is meant to fix. And the problem, it turns out, is an enzyme that most of your cells could not live without.
The enzyme is GRK2, and on a normal day it does unglamorous work. It helps cells read incoming signals correctly, in the heart, in the brain, pretty much everywhere.
But Quitterer, Professor of Molecular Pharmacology at ETH Zurich, and her team found that in Alzheimer’s brains a corrupted version of GRK2 shows up in alarming quantities. Cells can switch the enzyme off through their own metabolism, and that switched-off form does something nasty: it clumps. In aged mice engineered to develop the disease, roughly 64 per cent of the GRK2 in one memory-critical brain region had collapsed into these aggregates, against less than 9 per cent in healthy animals. The clumps drift toward the mitochondria, the tiny power plants inside every neuron, and settle there like grit in an engine.
What happens next is the part that should worry anyone who has watched a relative fade.
“The GRK2 aggregates block the pores of the mitochondria, reducing the amount of energy they can supply and leading to a situation of stress inside the cells,” says Quitterer. Starved and stressed, the neurons start producing more amyloid beta, the protein fragment that has dominated Alzheimer’s research for decades. And here is the cruel twist. That extra amyloid stresses the cells further, which produces still more broken GRK2, which makes more amyloid. Round and round it goes.
The team traced exactly what the rogue enzyme grabs hold of: a small mitochondrial protein called TOMM6, whose ordinary job is helping to keep the power plant’s import machinery assembled. Trapped by the aggregates, TOMM6 stops doing that job, and the mitochondria suffer for it.
Breaking the Circle
So the question Quitterer’s group set themselves was blunt: could you persuade GRK2 to stay in its functional form? They built a series of small molecules and tested them in cell cultures and in mice, and one candidate, the now-familiar Compound 10, did the trick. It nudges the equilibrium back toward healthy, monomeric GRK2 and away from the clumping form. With the enzyme behaving again the mitochondria recovered, amyloid deposits shrank, and the neurons that would otherwise have died simply carried on living. Mice given the compound orally from middle age survived longer than untreated ones. The molecule slips across the blood-brain barrier readily, which is no small thing for a drug aimed at the brain, and across more than 40 other pharmacological targets it left no fingerprints, a reassuring sign on the safety front.
There were odder effects, too. Treated animals showed better heart function and, charmingly, fewer grey hairs in old age.
None of this came quickly, and Quitterer is candid about why. “It took so long simply because everything takes so long in Alzheimer’s research,” she says. Because the disease is one of aging, the experiments demand old mice, animals of perhaps one and a half to two years, and each round of work eats another eighteen months or more before it yields anything you can build on. “It’s all a great deal slower than in cancer research, for example.”
A Different Door
What makes the finding interesting is not that it promises a cure, because it does not. “Alzheimer’s is a very complex disease,” Quitterer notes, and today’s drugs at best delay the slide by a matter of months. The value lies in the direction of attack. “That’s why it’s so important that we’ve now identified a new target protein in the form of GRK2, as well as an active ingredient that operates via GRK2 and therefore via a different mechanism than existing Alzheimer’s drugs,” she says. A drug that works by a wholly different route might, one day, be paired with the ones we already have.
The caveats are real and the team does not hide them. The roots of the project reach back to brain tissue collected during tumour surgery at the Ain Shams University Hospital in Cairo, and the human side of the evidence rests on a mere handful of patients, a limitation Quitterer’s group flags plainly. Everything else, for now, lives in mice and cell dishes, and the long graveyard of Alzheimer’s drugs that shone in rodents and failed in people is a warning nobody in the field forgets.
Still, there is something compelling about a target that sits at the crossing point of amyloid, faulty mitochondria and the broader machinery of aging, rather than chasing any one of them alone. ETH Zurich has filed for a patent and is now hunting for a company willing to carry Compound 10 toward an actual drug. Whether it gets there is anyone’s guess. But after two decades of patient acquaintance, Quitterer has at least handed the field a new door to try.
Full study: Cell Reports Medicine, DOI 10.1016/j.xcrm.2026.102707
Frequently Asked Questions
Why would an enzyme the body needs end up causing harm?
GRK2 is essential in its normal, working form, but cells can chemically switch it off, and in Alzheimer’s brains that inactive version builds up and clumps together. The clumps settle on mitochondria and choke their energy supply, which sets off a damaging cascade. So the trouble is not the enzyme itself but a corrupted form of it accumulating where it should not.
How is this different from the amyloid-targeting drugs we already have?
Most current Alzheimer’s treatments aim directly at amyloid beta or its plaques. This approach goes upstream, stabilising GRK2 so the chain reaction that pumps out amyloid never gets going in the first place. Because it works through an entirely separate mechanism, researchers think it could one day be combined with existing drugs rather than replacing them.
Is Compound 10 something patients could take soon?
Not yet, and possibly not for years. The results so far come from mice and laboratory cell cultures, with only a small number of human tissue samples backing them up. The basic research is finished and a patent is filed, but the molecule still needs a commercial partner and the full gauntlet of human trials before anyone could call it a medicine.
Why did the research take almost twenty years?
Alzheimer’s is a disease of aging, so the experiments need elderly mice, and growing them plus running each study can take well over a year apiece. As the lead researcher puts it, the whole field moves far more slowly than something like cancer research. That glacial pace is part of why genuinely new drug targets are so rare.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.